Kontrowersje związane z moralnym uzasadnieniem ochrony patentowej w biotechnologii

• Authors: Adam Karbowski

Title variants

Kontrowersje związane z moralnym uzasadnieniem ochrony patentowej w biotechnologii

• Languages of publication: PL

Abstracts

PL

-

EN

The following paper presents and discusses controversies over the moral justification for patent protection in biotechnology. Special emphasis was put on the controversy over the moral justification for patent protection of stem cells. By referring to arguments of (i) human dignity and (ii) patentability criteria, the moral justifiability of patent protection of stem cells was put in serious doubt. In a further section of the paper, the moral problems linked to patent protection in biotechnology were shown in a broader political and economic view. In that section of the paper, the preliminary concept of solving some of the discussed problems was sketched out (i.e. the introduction of decision criteria based on the system of values shared by the members of a given society).

Keywords

PL

-; -

EN

moral justification; patents; biotechnology

• Publisher: Uniwersytet Łódzki. Wydawnictwo Uniwersytetu Łódzkiego
• Journal: Annales. Etyka w Życiu Gospodarczym
• Year: 2017
• Volume: 20
• Issue: 1
• Pages: 83-94

Dates

published

2017-06-09

Contributors

author

Adam Karbowski

• Warsaw School of Economics, Chair of Economics II

References

• Alison M.R., R. Poulsom, S. Forbes, N.A. Wright, An introduction to stem cells. Review, „The Journal of Pathology” 2002, vol. 197, s. 419–423.
• Andorno R., Human Dignity and Human Rights as a Common Ground for a Global Ethics, „Journal of Medicine and Philosophy” 2009, vol. 34, s. 223–240.
• Bahadur G., M. Morrison, Patenting Human Pluripotent Cells: Balancing Commercial, Academic and Ethical Interests, „Human Reproduction” 2010, vol. 25, s. 14–21.
• Bishop A.E., D.K. Lee, J.M. Polak, Embryonic stem cells. Review, „The Journal of Pathology” 2002, vol. 197, s. 424–429.
• Blau H.M., T.R. Brazelton, J.M. Weissman, The evolving concept of stem cell: entity or function, „Cell” 2001, vol. 105, s. 829–841.
• Boldrin M., D.K. Levine, The Case against Patents, „Journal of Economic Perspectives” 2013, vol. 27, s. 3–22.
• Chakma J., S.M. Sammut, A. Agrawal, Life sciences venture capital in emerging markets, „Nature Biotechnology” 2013, vol. 31, s. 195–201.
• Cogle C.R., S.M. Guthrie, R.C. Sanders, W.L. Allen, E.W. Scott, B.E. Petersen, An overview of stem cell research and regulatory issues, „Mayo Clin. Proc.” 2003, vol. 8, s. 993–1003.
• Devaiah V.H., Impact of bioethics on patentability of inventions, „Indian Journal of Medical Ethics” 2010, vol. 7, s. 14–17.
• Drahos P., Biotechnology patents, markets and morality, „E.I.P.R.” 1999, vol. 21, s. 441–449.
• Grubb P.W., Patents for Chemicals, Pharmaceuticals and Biotechnology: Fundamentals of Global Law, Practice and Strategy, Oxford University Press, Oxford 2004.
• Habermas J., Przyszłość natury ludzkiej. Czy zmierzamy do eugeniki liberalnej?, Scholar, Warszawa 2003.
• Holland S., K. Lebacqz, L. Zoloth, The Human Embryonic Stem Cell Debate: Science, Ethics, and Public Policy, MIT Press, Cambridge 2001.
• Inoue H., N. Nagata, H. Kurokawa, S. Yamanaka, iPS cells: a game changer for future medicine, „The EMBO Journal” 2014, vol. 33, s. 409–417.
• Kamieniarz K., R. Nawrot, K. Grajek, A. Goździcka-Józefiak, Biotechnologia w medycynie regeneracyjnej i reprodukcyjnej, „Biotechnologia” 2006, vol. 73, s. 31–48.
• Kant I., Uzasadnienie metafizyki moralności, Wydawnictwo Marek Derewiecki, Kęty 2014.
• Karbowski A., J. Prokop, Controversy over the economic justifications for patent protection, „Procedia – Economics and Finance” 2013, vol. 5, s. 393–402.
• Khachiauri S., Human Embryonic Stem Cell Controversy (Patents Involving Ethical and Human Rights Concern), Lund University, Lund 2012.
• Krueger A.O., The Political Economy of the Rent-Seeking Society, „American Economic Review” 1974, vol. 64, s. 291–303.
• Lemke T., Biopolityka, przeł. Tomasz Dominiak, Sic!, Warszawa 2010.
• Liberda Z.B., Patenty w skali światowej i w poszczególnych krajach [w:] Tendencje innowacyjnego rozwoju polskich przedsiębiorstw, red. A. Zachorowska-Mazurkiewicz, E. Okoń-Horodyńska, Instytut Wiedzy i Innowacji, Warszawa 2008.
• Looney B., Should genes be patented?, „Law and Policy in International Business” 1994, vol. 26, s. 231–272.
• Machlup F., An Economic Review of The Patent System, United States Government Printing Office, Washington 1958.
• Oman R., Biotech patenting issues raise ethical concerns, „The National Law Journal” 1995, vol. 17, s. C42.
• Puri M.C., A. Nagy, Concise Review: Embryonic Stem Cells Versus Induced Pluripotent Stem Cells: The Game is on, „Stem Cells” 2012, vol. 30, s. 10–14.
• Resnik D.B., Embryonic Stem Cell Patents and Human Dignity, „Health Care Analysis” 2007, vol. 15, s. 211–222.
• Resnik D.B., Owning the Genome: A moral analysis of DNA patenting, State University of New York Press, New York 2004.
• Rothhaar M., Human Dignity and Human Rights in Bioethics: the Kantian Approach, „Medicine, Health Care and Philosophy” 2010, vol. 13, s. 251–257.
• Senser O., Kant’s Conception of Human Dignity, „Kant Studien” 2009, vol. 100, s. 309–331.
• Sikora M., W. Olszewski, Komórki macierzyste – biologia i zastosowanie terapeutyczne, „Postępy Higieny i Medycyny Doświadczalnej” 2004, vol. 58, s. 202–208.
• Sterckx S., The Moral Justifiability of Patents, „Ethical Perspectives: Journal of the European Ethics Network” 2006, vol. 13, s. 249–265.
• Warrington A.M., Private and Public Morality, „Canadian Medical Association Journal” 1964, vol. 90, s. 1326.
• Wiśniewska J., Motywy podejmowania bezpośrednich inwestycji zagranicznych, „Przegląd Organizacji” 2008, vol. 12, s. 19–23.
• Wojciszke B., Psychologia społeczna, Scholar, Warszawa 2011.
• Yamanaka S., Induced Pluripotent Stem Cells: Past, Present and Future, „Cell Stem Cell” 2012, vol. 10, s. 678–684

Identifiers

DOI

10.18778/1899-2226.20.1.06